EPO Patent Application: Antibodies Targeting Itga2 and Antibody-Drug Conjugates
Summary
The European Patent Office published patent application EP4545563A1 concerning antibodies targeting Itga2 and antibody-drug conjugates. The application lists Foreseen Technology (Beijing) Co., Ltd. and Foreseen Biotechnology (Shanghai) Co., Ltd. as applicants.
What changed
This document is a publication of a European Patent Office (EPO) patent application, EP4545563A1, titled 'Antibodies targeting Itga2, antibody-drug conjugates, EP4545563A1'. The publication date is March 18, 2026. The applicants are Foreseen Technology (Beijing) Co., Ltd. and Foreseen Biotechnology (Shanghai) Co., Ltd. The application details antibodies targeting Itga2 and antibody-drug conjugates comprising the same.
This is a patent application publication, not a regulatory rule or enforcement action. It does not impose new compliance obligations or deadlines on regulated entities. Companies in the pharmaceutical and biotechnology sectors may wish to review this patent filing for competitive intelligence or potential licensing opportunities.
Source document (simplified)
ANTIBODIES TARGETING ITGA2 AND ANTIBODY-DRUG CONJUGATES COMPRISING SAME
Publication EP4545563A1 Kind: A1 Mar 18, 2026
Applicants
Foreseen Technology (Beijing) Co., Ltd., Foreseen Biotechnology (Shanghai) Co., Ltd.
Inventors
WONG, Catherine C., LI, Wei, HAN, Pei
IPC Classifications
C07K 16/28 20060101AFI20240105BHEP A61K 39/00 20060101ALI20240105BHEP A61K 39/395 20060101ALI20240105BHEP A61P 35/00 20060101ALI20240105BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Pharma (A61K) publishes new changes.